Leap Therapeutics, Inc.
LPTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | -$0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | -$0 | $0 | $0 | -$0 |
| % Margin | -9,631.6% | – | – | -4,461.5% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -12,049.8% | – | – | -8,629.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -12,425.4% | – | – | -17,166.2% |
| EPS Diluted | -0.08 | -0.4 | -0.37 | -0.37 |
| % Growth | 80% | -8.1% | 0% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |